Ameriprise Financial Inc. Has $5.85 Million Stock Holdings in Celcuity Inc. (NASDAQ:CELC)

Ameriprise Financial Inc. boosted its position in Celcuity Inc. (NASDAQ:CELC) by 45.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 447,171 shares of the company’s stock after buying an additional 140,642 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.20% of Celcuity worth $5,853,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Summit Investment Advisors Inc. raised its position in Celcuity by 49.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock valued at $45,000 after buying an additional 1,132 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Celcuity during the 4th quarter worth approximately $50,000. The Manufacturers Life Insurance Company acquired a new position in shares of Celcuity during the 4th quarter worth approximately $142,000. Bleakley Financial Group LLC acquired a new position in shares of Celcuity during the 4th quarter worth approximately $146,000. Finally, Trexquant Investment LP acquired a new position in shares of Celcuity during the 4th quarter worth approximately $152,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Stock Down 2.9%

NASDAQ:CELC opened at $10.44 on Friday. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $395.32 million, a price-to-earnings ratio of -4.00 and a beta of 0.56. Celcuity Inc. has a twelve month low of $7.58 and a twelve month high of $19.77. The stock’s 50 day moving average price is $10.19 and its two-hundred day moving average price is $11.53.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.09. Equities research analysts expect that Celcuity Inc. will post -2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Celcuity in a research report on Thursday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Celcuity in a research report on Monday, May 19th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $30.80.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.